German and Austrian drug agencies intensify cooperation in the regulation of allergen products
A team from the Austrian Federal Office for Safety in Health Care (BASG) visited the Paul-Ehrlich-Institut (PEI) on 14 January 2019. The aim was to work more closely together in the future on how to regulate medicines for the diagnosis and immunotherapies of allergies.
Note for Wholesalers and Parallel Distributors of Avastin and Herceptin of French Origin – Suspected Illegal Export
The Paul-Ehrlich-Institut (PEI) has indicated that those medicinal products Avastin and Herceptin which are of French origin be classified as illegal with a high probability, if exported from France and marketed/sold on other European markets.
Issue 4/2018 of the Pharmacovigilance Bulletin is online
The current Pharmacovigilance Bulletin reports on the world-wide call for reporting suspected cases of adverse effects, and on the new online portal, which has been optimised for patients and their relatives. Other topics include the risk of aorta aneurysms and dissections by fluoroquinolones, and KidSafe – improved provision of medicines to children and adolescents.